SUBSCRIBE
SUBSCRIBE

Autobahn Therapeutics

NEWS
Biotech Beach
Autobahn Therapeutics Takes Aim at CNS Disorders with $76 Million Series B
This morning, the company officially launched with a Series B funding round backed by some of the biggest names in the life sciences, including Bristol Myers Squibb, Biogen and Pfizer.
June 9, 2020
 · 
2 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Press Releases
Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects
June 4, 2026
 · 
9 min read
Press Releases
Autobahn Therapeutics to Participate in Multiple Upcoming June 2026 Investor Conferences
May 27, 2026
 · 
1 min read
Press Releases
Autobahn Therapeutics Announces U.S. FDA Fast Track Designation for Elunetirom, a CNS-Directed Thyroid Hormone Receptor Agonist, for the Adjunctive Treatment of Bipolar Depression
May 26, 2026
 · 
4 min read
Press Releases
Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures
May 20, 2026
 · 
4 min read
Press Releases
Autobahn Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
 · 
1 min read
Press Releases
Autobahn Therapeutics Presents New Preclinical Data at ACNP Annual Meeting Supporting Novel Restorative Neuroplasticity Mechanism of Elunetirom
January 19, 2026
 · 
4 min read
Press Releases
Autobahn Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
 · 
1 min read
Press Releases
Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
November 11, 2025
 · 
1 min read
Press Releases
Autobahn Therapeutics to Participate in Multiple Upcoming September 2025 Investor Conferences
August 25, 2025
 · 
1 min read
Press Releases
Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference
July 9, 2025
 · 
1 min read
Load More